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Introduction
Antibodies against PD-1, a checkpoint in the effector phase of cytotoxic T cells, have been successfully used in cancer immunotherapy(1-3). Through the binding to PD-1, its ligands, namely PD-L1 and PD-L2, inhibit T cell-mediated immune responses. By preventing the binding of PD-L to PD-1, the FDA-approved antibodies pembrolizumab and nivolumab promote T cell-mediated cytotoxic responses which result in tumor regression in a variety of cancers (2) . In several randomized pivotal studies pembrolizumab and nivolumab demonstrated improved overall response rates and progression-free survival compared to chemotherapy or the anti-CTLA-4 antibody ipilimumab(4-7).
Besides efficacy, the introduction of anti-PD-1 antibodies led to a new benchmark for treatment tolerability in cancer being a treatment with very few adverse events. Adverse cutaneous reactions have however been reported. These include skin exanthemas with a frequency of 10-25% and vitiligo in 9-11% of the treated patients (2, 4, 5) . Robert et al. hypothesize that vitiligo is associated with a favorable outcome of anti-PD-1 therapy (8) . Moreover, one case of bullous pemphigoid in association with pembrolizumab (9) and one case of psoriasiform exanthema under nivolumab (10) Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous drug eruptions characterized by widespread macules, papules and/or targetoid lesions with varying degrees of epidermal necrolysis clinically presenting as skin detachment and/or bullous skin lesions with mucosal erosions (11) . Common drugs inducing SJS/TEN include allopurinol, trimethoprimsulfamethoxazole, carbamazepin, lamotrigine, nevirapin, NSAIDS, phenobarbital and phenytoin (12) .
The molecular events that cause potentially fatal SJS and TEN are only partially understood, although "drug"-specific adaptive immune responses in the effector phase of TEN are well documented (13) . In the skin, T cell-mediated immune responses occurring during SJS/TEN result in a massive keratinocyte apoptosis mediated by cytolytic molecules including FasL (14) , perforin/granzyme B(15), annexin A1(16) and granulysin (17) . Histologically SJS and TEN are characterized by full-thickness epidermal necrolysis due to extensive keratinocyte apoptosis associated with varying degrees of inflammation and epidermal infiltration by CD8+ lymphocytes.
Research. In this study we aimed to systematically assess and characterize the adverse cutaneous reactions observed in advanced melanoma patients treated with anti-PD-1 antibodies using gene expression profiling and compared the data to other clinical types of drug eruptions.
Patients and Methods
Advanced melanoma patients were treated with either the anti-PD-1 antibody pembrolizumab (2mg/kg or 10mg/kg) or with nivolumab (3mg/kg) within clinical trials (clinicaltrials.gov NCT01704287, NCT01721746 and NCT02156804)(4, 7) and early access program. The first 68 melanoma patients treated with pembrolizumab or nivolumab at the University of Zurich were systematically investigated for adverse skin reactions by board certified dermatologists experienced in immunotherapy and familiar with associated adverse events (SMG and/or RD).
Complete and accurate skin examinations were performed before and during immunotherapy.
Selected previously untreated skin eruptions of 8 patients emerging during therapy were biopsied and analyzed by histology. The decision to take a biopsy was based on whether the lesion was new (i.e. not apparent prior treatment start), on the severity (grade 2 or greater), on the localization and distribution (favoring multiple and disseminated lesions) and on the clinical characteristics (palpable or scaling presentation). In general, the most infiltrated lesion was chosen and biopsied provided patient's consent and that the lesion was in a region of the body that allowed proper wound healing.
Expression of PD-1 on skin infiltrating T-cells (eBioscience, San Diego, CA) and PD-L1 (Immunobiology Yale, New Haven, CT) on keratinocytes at the foci of lymphocytic epidermal infiltration was assessed by immunohistochemistry.
Gene expression analysis of 5 out of these 8 skin biopsies during anti-PD-1 therapy with pembrolizumab were in addition analyzed and compared to expression profiles of skin biopsies from patients with maculopapular rashes (MPR) (n=8), SJS/TEN (n=5), and cutaneous graft-versus-host disease (GVHD) (n=9). RNA was isolated from patients skin (n=5) and from healthy control skin (n=4) using a Qiagen RNeasy kit (Qiagen) following manufacturer's instructions, and total RNA was converted into cDNA by standard reverse transcription using a RevertAid RT Reverse Transcription Kit (Thermo Scientific). Quantitative PCR was performed using Power SYBR Green PCR Master Mix
Research. Moreover, we performed gene expression arrays (Affymetrix) on skin of MPR patients (n=8), SJS/TEN patients (n=5), GVHD patients (n=9) and healthy donors (n=8) as controls. Healthy skin was obtained from healthy individuals undergoing plastic surgery. All human skin biopsies were collected with informed written consent upon approval of local ethical committees and were conducted according to the Declaration of Helsinki Principles (KEK Nr. 647). Based on the results of the gene expression arrays, we selected a set of genes that could be used as specific signature for TEN as opposed to MPR and GVHD ( Figure 2A ). Using quantitative RT-PCR we determined the expression levels of the gene set specific for SJS/TEN in the skin of patients with an adverse cutaneous reaction occurring during anti-PD-1 therapy.
Results
Between Feb 2013 and Sept 2015, 68 patients were treated with either pembrolizumab 2mg/kg, 10mg/kg (every three weeks), or nivolumab 3mg/kg (every two weeks) in different clinical trials (clinicaltrials.gov NCT01704287, NCT01721746 and NCT02156804)(4, 7) and early access program.
Out of the first 68 stage IV melanoma patients treated with pembrolizumab (n=54) or nivolumab (n=14) at the University Hospital of Zurich 15 patients (22%) developed any cutaneous inflammatory reaction and 10 (15%) a vitiligo. Clinically, the adverse cutaneous reactions ranged from small erythematous papules with mild pruritus to disseminated erythematous maculopapular rashes without major clinical signs of epidermal involvement to severe maculopapular rashes including epidermal detachment and mucosal involvement (Table 1) . Histology performed on selected lesional skin biopsies of 8 patients at onset of the adverse cutaneous reaction revealed different manifestation grades of apoptotic keratinocytes and even focal full thickness necrosis of the epidermis in two cases in the histology (Table 1) . In particular, a 77 year-old patient presented with a generalized unspecific maculopapular rash predominantly affecting the trunk with focal areas of epidermal detachment a few days after the first pembrolizumab infusion ( Figure 1A , <10% of the body surface area). Histology showed epidermal damage with apoptotic keratinocytes, subepidermal lymphocytic infiltrates and dermo-epidermal In all cases, none of the concomitant medications taken by patients had been recently started or were known to cause SJS/TEN (Table 1) . Furthermore, lymphocyte transformation tests to the concomitant medication taken by the patient 1 did not provide evidence for a "drug"-specific immune response (data not shown) ( Table 1) .
Treatment included systemic steroids (prednisone 1mg/kg, tapered for 4 weeks), systemic steroids (over a course of 4 weeks), disinfectant agents when necessary, and re-hydratation of the skin.
Treatment with pembrolizumab could be continued in 4/6 cases and did not further affect the skin.
Gene expression profiling of RNA extracted from lesional skin of validated cases of MPR (8 cases), SJS/TEN (5 cases) and cutaneous GVHD (9 cases) enabled us to identify a set of 18 genes for which the expression levels enable differentiation between the three diagnostic categories (Figure 2A) .
Analysis of the level of expression of these 18 genes was performed in the lesional skin biopsies of 5 patients, and revealed a gene expression profile reminiscent of SJS/TEN (Fig 2B) . Both SJS/TEN skin (n=5) and skin of 5 patients presenting an adverse cutaneous reaction upon anti-PD-1 therapy had significant upregulation of Elafin, SPRR2B, Granzyme B, CXCL9, CXCL10 and CXCL11 whereas expression of Desmocollin 3, Loricrin, Filaggrin and Keratin 1 were similar to those in healthy skin.
Research. Clinical and histological features of the lesions striking resemble the findings reported in mice with a disrupted PD-1 gene (22) . These mice develop a lupus-like inflammatory syndrome with proliferative glomerulonephritis, arthritis with sometimes granulomatous inflammation and skin lesions-reported as "dermatitis-like lesions, necrotic lesions and erythema" (22) . The histologies of the skin of these mice present features compatible with lichen planus including acanthosis, hypergranulosis and apoptotic keratinocytes together with a lymphocytic infiltrate of the grenz zone of the basal membrane resulting in a vacuolization and sometimes split formation (22) .
The histological analysis of these human adverse cutaneous reaction cases demonstrated signs of a The exact pathomechanism of the adverse cutaneous reactions occurring upon pembrolizumab and nivolumab therapy remains to be elucidated. While vitiligo can be considered as a successful (re)-activation of T cells with a repertoire specific to melanocyte antigens, the induction of a cytotoxic response to keratinocytes was not expected, and is indicative of the activation of T cells with nonmelanoma-derived self-antigen specificity(ies). Interestingly, both vitiligo and/or cutaneous reactions emerging during nivolumab treatment in melanoma patients have recently been reported to be associated with overall survival (23) . As a consequence, cutaneous reactions during anti-PD-1 treatment could potentially be used as biomarkers in the therapy. Although larger prospective analyses are still needed to validate this association, detection and diagnosis of cutaneous reactions during anti-PD-1 therapy gain further importance in this context. By inhibiting T cell activation and sustaining Tregs(24), the PD-1/PD-L pathway plays a major role in peripheral tolerance including transplant (25) and feto-maternal tolerance (26) . The concept of a tolerogenic role for PD-1/PD-1L has emerged from observations that PD-1-deficient mice develop autoimmune pathologies (27) 
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from occurring. In line with this, it has been recently reported that, in a mouse model that PD-L1 expressed on keratinocytes presenting self-antigens, regulates autoreactive CD8 + T cell activity, and prevents the development of cutaneous autoimmune disease (28) . The reason for which cutaneous adverse events in anti-PD-1-treated patients can vary from vitiligo to SJS-like reactions remains unknown and larger series of subjects would be required to assess this. A detailed characterization of the T cells causing damage to healthy tissues in patients treated with anti-PD-1 antibodies as well as complementary skin investigations in patients without adverse skin reactions would be of interest for a better understanding and, ultimately, the prevention of such severe forms of adverse cutaneous reactions.
Research. 
